IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -707 Thousand USD | -261.17% |
| 2022 | 1.29 Million USD | -52.46% |
| 2021 | 1.48 Million USD | 102.08% |
| 2020 | 1.05 Million USD | 931.87% |
| 2019 | 459 Thousand USD | 93.28% |
| 2018 | -634 Thousand GBP | 34.69% |
| 2017 | -1.18 Million GBP | 32.19% |
| 2016 | -2.02 Million GBP | -235.71% |
| 2015 | -998 Thousand GBP | 38.28% |
| 2014 | -1.04 Million GBP | 67.02% |
| 2013 | -5.15 Million GBP | 44.41% |
| 2012 | -9.26 Million GBP | -9.08% |
| 2011 | -8.49 Million GBP | -92.86% |
| 2010 | -4.4 Million GBP | -35.28% |
| 2009 | -3.67 Million GBP | -23.46% |
| 2008 | -2.63 Million GBP | 0.0% |
| 2007 | - GBP | 100.0% |
| 2006 | -6.5 Million GBP | -68.68% |
| 2005 | -3.85 Million GBP | 44.31% |
| 2004 | -6.9 Million GBP | -24.15% |
| 2003 | -5.57 Million GBP | -51.73% |
| 2002 | -3.71 Million GBP | -33.69% |
| 2001 | -2.73 Million GBP | -33.04% |
| 2000 | -2.05 Million GBP | 27.6% |
| 1999 | -3 Million GBP | 16.25% |
| 1998 | -3.42 Million GBP | -15.66% |
| 1997 | -2.94 Million GBP | -617.8% |
| 1996 | -410 Thousand GBP | -205.13% |
| 1995 | 389 Thousand GBP | 119.57% |
| 1994 | -2.02 Million GBP | -198.8% |
| 1993 | -665 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.02 Million USD | 0.0% |
| 2023 FY | - USD | -261.17% |
| 2023 Q2 | -965.67 Thousand USD | 0.0% |
| 2023 Q4 | -497.63 Thousand USD | 0.0% |
| 2022 Q4 | 843.69 Thousand USD | 0.0% |
| 2022 Q2 | 187.8 Thousand USD | 0.0% |
| 2022 FY | - USD | -52.46% |
| 2021 Q2 | 982.34 Thousand USD | 0.0% |
| 2021 Q4 | 847.38 Thousand USD | 0.0% |
| 2021 FY | - USD | 102.08% |
| 2020 Q4 | 506.77 Thousand USD | 0.0% |
| 2020 FY | - USD | 931.87% |
| 2020 Q2 | 367.02 Thousand USD | 0.0% |
| 2019 FY | - USD | 93.28% |
| 2019 Q4 | 67.77 Thousand USD | 0.0% |
| 2018 FY | - GBP | 34.69% |
| 2017 FY | - GBP | 32.19% |
| 2016 FY | - GBP | -235.71% |
| 2015 FY | - GBP | 38.28% |
| 2014 FY | - GBP | 67.02% |
| 2013 FY | - GBP | 44.41% |
| 2012 FY | - GBP | -9.08% |
| 2011 FY | - GBP | -92.86% |
| 2010 FY | - GBP | -35.28% |
| 2009 FY | - GBP | -23.46% |
| 2008 FY | - GBP | 0.0% |
| 2007 FY | - GBP | 100.0% |
| 2006 FY | - GBP | -68.68% |
| 2005 FY | - GBP | 44.31% |
| 2004 FY | - GBP | -24.15% |
| 2003 FY | - GBP | -51.73% |
| 2002 FY | - GBP | -33.69% |
| 2001 FY | - GBP | -33.04% |
| 2000 FY | - GBP | 27.6% |
| 1999 FY | - GBP | 16.25% |
| 1998 FY | - GBP | -15.66% |
| 1997 FY | - GBP | -617.8% |
| 1996 FY | - GBP | -205.13% |
| 1995 FY | - GBP | 119.57% |
| 1994 FY | - GBP | -198.8% |
| 1993 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.005% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 88.075% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.898% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 95.93% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.752% |
| Mesoblast Limited | -62.38 Million USD | 98.867% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 53.973% |
| Genus plc | 73.7 Million USD | 100.959% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 89.307% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 80.068% |
| Marizyme, Inc. | -34.28 Million USD | 97.938% |
| ContraFect Corporation | -64.99 Million USD | 98.912% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 91.94% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 84.38% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 49.565% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 73.265% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 69.576% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -36.474% |
| Accustem Sciences Inc. | -3.74 Million USD | 81.129% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.534% |
| EV Biologics, Inc. | -1.26 Million USD | 44.205% |
| Q BioMed Inc. | -617.62 Thousand USD | -14.47% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 119.793% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -11.795% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 69.052% |
| Biomind Labs Inc. | -1.03 Million USD | 31.661% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 107.158% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 90.127% |
| Skye Bioscience, Inc. | -13.54 Million USD | 94.781% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 52.468% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -2728.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 81.799% |
| IMV Inc. | -35.52 Million USD | 98.01% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.545% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 71.742% |
| GB Sciences, Inc. | -1.41 Million USD | 50.207% |
| Alpha Cognition Inc. | -9.7 Million USD | 92.716% |
| HST Global, Inc. | -5303.00 USD | -13232.076% |
| CSL Limited | 4.78 Billion USD | 100.015% |
| Halberd Corporation | -74.27 Thousand USD | -851.817% |
| Enzolytics Inc. | -2.12 Million USD | 66.683% |
| Resverlogix Corp. | -11.74 Million USD | 93.979% |
| Affymax, Inc. | -14.29 Million USD | 95.054% |
| SYBLEU INC | -141.57 Thousand USD | -399.396% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 76.918% |
| argenx SE | -216.02 Million USD | 99.673% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.722% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 158.094% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 52.832% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 286.62% |
| AVAX Technologies, Inc. | -6.11 Million USD | 88.434% |
| Zenith Capital Corp. | -8.6 Million USD | 91.785% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.716% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3958.32% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 71.101% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -301.649% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 98.216% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 75.556% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 32.429% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 10614.575% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 59.6% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 63.195% |
| BioStem Technologies, Inc. | -7.55 Million USD | 90.64% |
| ONE Bio Corp. | 13.61 Million USD | 105.194% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -290.418% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 65.63% |
| Agentix Corp. | -1.37 Million USD | 48.46% |
| LadRx Corporation | 412.28 Thousand USD | 271.484% |
| Cell Source, Inc. | -4.27 Million USD | 83.452% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -92.527% |
| Regen BioPharma, Inc. | 1.46 Million USD | 148.228% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 24.542% |
| NovAccess Global Inc. | -1.03 Million USD | 31.677% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 107.985% |
| Itoco Inc. | -1.86 Million USD | 62.172% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -86.239% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 36.649% |
| Kadimastem Ltd | -2.62 Million USD | 73.06% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -195.63% |
| CytoDyn Inc. | -18.02 Million USD | 96.079% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -794.608% |
| Mobile Lads Corp. | -2.24 Million USD | 68.454% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -5681.339% |
| Qrons Inc. | -40.08 Thousand USD | -1663.928% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -45.57% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 234.045% |
| Rebus Holdings, Inc. | -951 Thousand USD | 25.657% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 33.428% |
| International Stem Cell Corporation | 202 Thousand USD | 450.0% |
| Bioxytran, Inc. | -3.82 Million USD | 81.493% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1243.085% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 71.283% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.029% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1471.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 74.178% |
| Neutra Corp. | -181.24 Thousand USD | -290.075% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 96.493% |
| PureTech Health plc | -11.62 Million USD | 93.919% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 96.493% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 90.8% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.538% |
| CSL Limited | 4.73 Billion USD | 100.015% |
| Cellectis S.A. | -92.63 Million USD | 99.237% |